Effectiveness of sacubitril–valsartan in cancer patients with heart failure
Abstract Aims Current guidelines recommend sacubitril/valsartan for patients with heart failure and reduced left ventricular ejection fraction (LVEF), but there is lack of evidence of its efficacy and safety in cancer therapy‐related cardiac dysfunction (CTRCD). Our aim was to analyse the potential...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-04-01
|
| Series: | ESC Heart Failure |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ehf2.12627 |
| _version_ | 1818588229255823360 |
|---|---|
| author | Ana Martín‐Garcia Teresa López‐Fernández Cristina Mitroi Marinela Chaparro‐Muñoz Pedro Moliner Agustin C. Martin‐Garcia Amparo Martinez‐Monzonis Antonio Castro Jose L. Lopez‐Sendon Pedro L. Sanchez |
| author_facet | Ana Martín‐Garcia Teresa López‐Fernández Cristina Mitroi Marinela Chaparro‐Muñoz Pedro Moliner Agustin C. Martin‐Garcia Amparo Martinez‐Monzonis Antonio Castro Jose L. Lopez‐Sendon Pedro L. Sanchez |
| author_sort | Ana Martín‐Garcia |
| collection | DOAJ |
| description | Abstract Aims Current guidelines recommend sacubitril/valsartan for patients with heart failure and reduced left ventricular ejection fraction (LVEF), but there is lack of evidence of its efficacy and safety in cancer therapy‐related cardiac dysfunction (CTRCD). Our aim was to analyse the potential benefit of sacubitril/valsartan in patients with CTRCD. Methods and results We performed a retrospective multicentre registry (HF‐COH) in six Spanish hospitals with cardio‐oncology clinics including all patients treated with sacubitril/valsartan. Demographic and clinical characteristics and laboratory and echocardiographic data were collected. Median follow‐up was 4.6 [1; 11] months. Sixty‐seven patients were included (median age was 63 ± 14 years; 64% were female, 87% had at least one cardiovascular risk factor). Median time from anti‐cancer therapy to CTRD was 41 [10; 141] months. Breast cancer (45%) and lymphoma (39%) were the most frequent neoplasm, 31% had metastatic disease, and all patients were treated with combination antitumor therapy (70% with anthracyclines). Thirty‐nine per cent of patients had received thoracic radiotherapy. Baseline median LVEF was 33 [27; 37], and 21% had atrial fibrillation. Eighty‐five per cent were on beta‐blocker therapy and 76% on mineralocorticoid receptor antagonists; 90% of the patients were symptomatic NYHA functional class ≥II. Maximal sacubitril/valsartan titration dose was achieved in 8% of patients (50 mg b.i.d.: 60%; 100 mg b.i.d.: 32%). Sacubitril/valsartan was discontinued in four patients (6%). Baseline N‐terminal pro‐B‐type natriuretic peptide levels (1552 pg/mL [692; 3624] vs. 776 [339; 1458]), functional class (2.2 ± 0.6 vs. 1.6 ± 0.6), and LVEF (33% [27; 37] vs. 42 [35; 50]) improved at the end of follow‐up (all P values ≤0.01). No significant statistical differences were found in creatinine (0.9 mg/dL [0.7; 1.1] vs. 0.9 [0.7; 1.1]; P = 0.055) or potassium serum levels (4.5 mg/dL [4.1; 4.8] vs. 4.5 [4.2; 4.8]; P = 0.5). Clinical, echocardiographic, and biochemical improvements were found regardless of the achieved sacubitril–valsartan dose (low or medium/high doses). Conclusions Our experience suggests that sacubitril/valsartan is well tolerated and improves echocardiographic functional and structural parameters, N‐terminal pro‐B‐type natriuretic peptide levels, and symptomatic status in patients with CTRCD. |
| first_indexed | 2024-12-16T09:21:26Z |
| format | Article |
| id | doaj.art-e8b9384e425e41ca8977b262e11b1e4d |
| institution | Directory Open Access Journal |
| issn | 2055-5822 |
| language | English |
| last_indexed | 2024-12-16T09:21:26Z |
| publishDate | 2020-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | ESC Heart Failure |
| spelling | doaj.art-e8b9384e425e41ca8977b262e11b1e4d2022-12-21T22:36:46ZengWileyESC Heart Failure2055-58222020-04-017276376710.1002/ehf2.12627Effectiveness of sacubitril–valsartan in cancer patients with heart failureAna Martín‐Garcia0Teresa López‐Fernández1Cristina Mitroi2Marinela Chaparro‐Muñoz3Pedro Moliner4Agustin C. Martin‐Garcia5Amparo Martinez‐Monzonis6Antonio Castro7Jose L. Lopez‐Sendon8Pedro L. Sanchez9Department of Cardiology Hospital Universitario de Salamanca—IBSAL, University of Salamanca Paseo de San Vicente 58‐187 37007 Salamanca SpainCIBERCV Instituto de Salud Carlos III Madrid SpainDepartment of Cardiology Hospital Puerta de Hierro—IDIPHISA, Majadahonda Madrid SpainDepartment of Cardiology Hospital Virgen de la Macarena—IBiS Seville SpainDepartment of Cardiology Hospital Universitari Germans Trias I Pujol—IGTP, Badalona Barcelona SpainDepartment of Cardiology Hospital Universitario de Salamanca—IBSAL, University of Salamanca Paseo de San Vicente 58‐187 37007 Salamanca SpainCIBERCV Instituto de Salud Carlos III Madrid SpainCIBERCV Instituto de Salud Carlos III Madrid SpainCIBERCV Instituto de Salud Carlos III Madrid SpainDepartment of Cardiology Hospital Universitario de Salamanca—IBSAL, University of Salamanca Paseo de San Vicente 58‐187 37007 Salamanca SpainAbstract Aims Current guidelines recommend sacubitril/valsartan for patients with heart failure and reduced left ventricular ejection fraction (LVEF), but there is lack of evidence of its efficacy and safety in cancer therapy‐related cardiac dysfunction (CTRCD). Our aim was to analyse the potential benefit of sacubitril/valsartan in patients with CTRCD. Methods and results We performed a retrospective multicentre registry (HF‐COH) in six Spanish hospitals with cardio‐oncology clinics including all patients treated with sacubitril/valsartan. Demographic and clinical characteristics and laboratory and echocardiographic data were collected. Median follow‐up was 4.6 [1; 11] months. Sixty‐seven patients were included (median age was 63 ± 14 years; 64% were female, 87% had at least one cardiovascular risk factor). Median time from anti‐cancer therapy to CTRD was 41 [10; 141] months. Breast cancer (45%) and lymphoma (39%) were the most frequent neoplasm, 31% had metastatic disease, and all patients were treated with combination antitumor therapy (70% with anthracyclines). Thirty‐nine per cent of patients had received thoracic radiotherapy. Baseline median LVEF was 33 [27; 37], and 21% had atrial fibrillation. Eighty‐five per cent were on beta‐blocker therapy and 76% on mineralocorticoid receptor antagonists; 90% of the patients were symptomatic NYHA functional class ≥II. Maximal sacubitril/valsartan titration dose was achieved in 8% of patients (50 mg b.i.d.: 60%; 100 mg b.i.d.: 32%). Sacubitril/valsartan was discontinued in four patients (6%). Baseline N‐terminal pro‐B‐type natriuretic peptide levels (1552 pg/mL [692; 3624] vs. 776 [339; 1458]), functional class (2.2 ± 0.6 vs. 1.6 ± 0.6), and LVEF (33% [27; 37] vs. 42 [35; 50]) improved at the end of follow‐up (all P values ≤0.01). No significant statistical differences were found in creatinine (0.9 mg/dL [0.7; 1.1] vs. 0.9 [0.7; 1.1]; P = 0.055) or potassium serum levels (4.5 mg/dL [4.1; 4.8] vs. 4.5 [4.2; 4.8]; P = 0.5). Clinical, echocardiographic, and biochemical improvements were found regardless of the achieved sacubitril–valsartan dose (low or medium/high doses). Conclusions Our experience suggests that sacubitril/valsartan is well tolerated and improves echocardiographic functional and structural parameters, N‐terminal pro‐B‐type natriuretic peptide levels, and symptomatic status in patients with CTRCD.https://doi.org/10.1002/ehf2.12627CancerCardio‐oncologyCardiotoxicityHeart failureSacubitril–valsartan |
| spellingShingle | Ana Martín‐Garcia Teresa López‐Fernández Cristina Mitroi Marinela Chaparro‐Muñoz Pedro Moliner Agustin C. Martin‐Garcia Amparo Martinez‐Monzonis Antonio Castro Jose L. Lopez‐Sendon Pedro L. Sanchez Effectiveness of sacubitril–valsartan in cancer patients with heart failure ESC Heart Failure Cancer Cardio‐oncology Cardiotoxicity Heart failure Sacubitril–valsartan |
| title | Effectiveness of sacubitril–valsartan in cancer patients with heart failure |
| title_full | Effectiveness of sacubitril–valsartan in cancer patients with heart failure |
| title_fullStr | Effectiveness of sacubitril–valsartan in cancer patients with heart failure |
| title_full_unstemmed | Effectiveness of sacubitril–valsartan in cancer patients with heart failure |
| title_short | Effectiveness of sacubitril–valsartan in cancer patients with heart failure |
| title_sort | effectiveness of sacubitril valsartan in cancer patients with heart failure |
| topic | Cancer Cardio‐oncology Cardiotoxicity Heart failure Sacubitril–valsartan |
| url | https://doi.org/10.1002/ehf2.12627 |
| work_keys_str_mv | AT anamartingarcia effectivenessofsacubitrilvalsartanincancerpatientswithheartfailure AT teresalopezfernandez effectivenessofsacubitrilvalsartanincancerpatientswithheartfailure AT cristinamitroi effectivenessofsacubitrilvalsartanincancerpatientswithheartfailure AT marinelachaparromunoz effectivenessofsacubitrilvalsartanincancerpatientswithheartfailure AT pedromoliner effectivenessofsacubitrilvalsartanincancerpatientswithheartfailure AT agustincmartingarcia effectivenessofsacubitrilvalsartanincancerpatientswithheartfailure AT amparomartinezmonzonis effectivenessofsacubitrilvalsartanincancerpatientswithheartfailure AT antoniocastro effectivenessofsacubitrilvalsartanincancerpatientswithheartfailure AT josellopezsendon effectivenessofsacubitrilvalsartanincancerpatientswithheartfailure AT pedrolsanchez effectivenessofsacubitrilvalsartanincancerpatientswithheartfailure |